A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis

A Phase 3, Multicenter, Open-label, Uncontrolled Trial to Evaluate the Efficacy and Safety of OPA-15406 Ointment in Infants Younger Than 2 Years of Age With Atopic Dermatitis


Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Source Otsuka Pharmaceutical Co., Ltd.
Brief Summary

To investigate the efficacy of 0.3% OPA-15406 ointment when administered twice daily for 4 weeks in infants younger than 2 years of age with Atopic Dermatitis

Overall Status Recruiting
Start Date 2022-05-01
Completion Date 2023-10-01
Primary Completion Date 2022-11-01
Phase Phase 3
Study Type Interventional
Primary Outcome
Measure Time Frame
Success rate in Investigator's Global Assessment (IGA) Week 4
Enrollment 40

Intervention Type: Drug

Intervention Name: OPA-15406

Description: 0.3% or 1% ointment, topical, twice daily, for 52 weeks

Arm Group Label: OPA-15406

Other Name: difamilast



Inclusion Criteria: - Subjects who are diagnosed with AD in accordance with the criteria of the Japanese Dermatological Association - Subjects whose AD affects 5% to 40% of BSA (excluding scalp) at the screening and baseline examinations - Subjects who have an IGA score of 2 or 3 at the screening and baseline examinations Exclusion Criteria: -Subjects who have an AD or contact dermatitis flare-up defined as a rapid intensification of AD, within 28 days prior to the baseline examination



Minimum Age:

3 Months

Maximum Age:

2 Years

Healthy Volunteers:


Overall Official
Last Name Role Affiliation
Takehisa Matsumaru Study Director Otsuka Pharmaceutical Co., Ltd.
Overall Contact

Last Name: Drug Information Center

Phone: +81-3-6361-7314

Facility: Status: Sotobo Children's Clinic
Location Countries


Verification Date


Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: OPA-15406

Type: Experimental

Patient Data Yes
Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News